Vicore Pharma Holding AB - American Depositary Shares (VCRE)

♥ 666 Thanks from members

Vicore Pharma Holding AB (VCRE) exhibits a cautiously neutral to bullish sentiment following its US Nasdaq dual listing, driven by a fully enrolled Phase 2b ASPIRE trial for buloxibutid in IPF and a cash runway extending into 2028.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Vicore Pharma Holding AB Leadership: Ahmed Mousa (CEO) Leadership: Hans Wigzell (Chairman) Holder: Hadean Ventures Holder: HealthCap Holder: Fjärde AP-fonden AT2 Receptor Agonists (C21) Idiopathic Pulmonary Fibrosis Therapeutics Rare Disease Treatments #VCRE #Vicore Pharma #Biotech ADSs #Pulmonary Fibrosis #NASDAQ VCRE